TrialJAMA ophthalmology2020

Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.

Eric R Crouch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.